| Literature DB >> 32698402 |
Hailey Pineau1,2,3, Valerie Sim1,2,3.
Abstract
Prion diseases are fatal, transmissible neurodegenerative disorders whose pathogenesis is driven by the misfolding, self-templating and cell-to-cell spread of the prion protein. Other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease, share some of these prion-like features, with different aggregation-prone proteins. Consequently, researchers have begun to apply prion-specific techniques, like the prion organotypic slice culture assay (POSCA), to these disorders. In this review we explore the ways in which the prion phenomenon has been used in organotypic cultures to study neurodegenerative diseases from the perspective of protein aggregation and spreading, strain propagation, the role of glia in pathogenesis, and efficacy of drug treatments. We also present an overview of the advantages and disadvantages of this culture system compared to in vivo and in vitro models and provide suggestions for new directions.Entities:
Keywords: Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; neurodegenerative disease; organotypic slice culture; prion; protein aggregation; protein misfolding
Mesh:
Substances:
Year: 2020 PMID: 32698402 PMCID: PMC7407827 DOI: 10.3390/biom10071079
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Schematic of coronal slice culture preparation, infection, and confocal imaging. (A) The brain is removed from 8- or 9-day-old mouse pups, the olfactory bulbs are removed, and the brain is hemisectioned sagitally. (B) The hemispheres are embedded in low-melting-point agarose gel and sliced into 275 µm-thick coronal sections with a vibratome. About 40 slices anterior-posterior are obtained from each mouse, with 4 slices cultured per well. Each well is considered a “region”, from 1 (anterior) to 10 (posterior), each representing 1100 µm. (C) The slices are then placed on Milicell cell culture inserts with the culture media below the membrane and can be cultured for as long as three months. During the culture period, genetically identical, location-matched slices can be used as controls or subjected to different treatment conditions in the absence of the blood–brain barrier, such as infection with different prion strains or treatment with different drugs. At various time points, the slices can be immunostained for confocal imaging. (D) Low magnification confocal image of an RML-infected slice that was cultured for 56 days post-infection. PrP (Saf83) is shown in green, microglia (Iba1) are shown in blue, reactive astrocytes (GFAP) are shown in cyan, neuronal nuclei (NeuN) are shown in red. As seen in the NeuN channel, the boundaries of distinct brain regions are discernable (scale = 500 µm). (E) High magnification confocal image of a neocortical region from the RML-infected slice in E, showing the array of cell types and architecture. (F) High magnification confocal image of an RML-infected slice showing PrP aggregates (green) and activated microglia (blue).
Figure 2Coronally sliced whole brain prion organotypic slice culture assay (POSCA) can propagate three rodent-adapted scrapie strains. (A) Immunoblots of proteinase K (PK)-digested PrP from slice homogenates of anterior (1) through posterior (10) cultured brain regions. Slices were infected with 22L, RML, or ME7 strain of rodent-adapted scrapie, then harvested at day 56 post-infection. All strains can be propagated in this system. Whether the different levels of PK-resistant PrP are strain-specific is the question of ongoing experiments. POSCA was prepared from C57Bl6 mice for all strains, with the same baseline PrPC levels. An amount of 50 µg total protein before PK digestion was loaded. (B) Anatomy of a slice from region 6 and heat maps for total PrP (PrPC plus PrPSc) of tga20* POSCA uninfected or infected with 22L and RML, showing different distributions of total PrP. Heat map values indicate relative amounts (percentiles of total PrP) within a slice, not absolute values of PrP, so it is the pattern of total PrP distribution, not the intensity of signal, that can be compared between slices. Unlike immunoblots which only provide total levels of a protein from a homogenate, slice culture allows analysis of regional variation within a single slice. * tga20 mice express wildtype mouse PrP at 6× fold higher levels and were the original mouse line used for the first POSCA experiments. PrP antibodies: Sha31 (A), SAF83 (B).
Advantages and disadvantages of organotypic slice culture vs. in vivo or cell culture studies.
| In Vivo | Slice Culture | Primary Culture | Simple Cell Culture | |
|---|---|---|---|---|
| Cost | + | ++ | ++ | +++ |
| Time | + | ++ | ++ | +++ |
| Ethics of animal use | + | ++ | ++ | +++ |
| Technical difficulty | + | ++ | ++ | +++ |
| Cell types, cyto-architecture | +++ | ++ | - | - |
| Genetics | ++ | +++ | + | - |
| Real time monitoring | ++ | +++ | +++ | +++ |
| Animal age | +++ | ++ | + | n/a |
| Vasculature | +++ | ++ | - | n/a |
+++ most advantageous; ++ less advantageous; + least advantageous. n/a indicates feature is not applicable in that model.
Overview of organotypic slice culture studies which have used the prion-like features of aggregate-prone proteins from other neurodegenerative diseases.
| Prion Feature | Amyloid Beta | Tau | α-Synuclein | TDP-43 | SOD1 | Huntingtin |
|---|---|---|---|---|---|---|
| Seeded aggregation | [ | [ | [ | [ | ||
| Prion-like spreading | [ | [ | [ | |||
| Pathology induced by seeding | [ | [ | [ | [ | ||
| Strains | [ | [ | [ | |||
| Drug screening (to prevent aggregation/spread) | [ | [ | [ | [ | [ |
Summary of in vivo and ex vivo experiments for prion-like protein aggregates, indicating type of mouse model used for culture and whether application of a prion-like seeding agent facilitated aggregation or pathology.
| Ref. | Animal Model | In Vivo Pathology | Unseeded Slice Pathology | Prion-Like Seeding Agent | Seeded Slice Pathology |
|---|---|---|---|---|---|
|
| |||||
| [ | ThS-positive plaques by 3 months | No ThS-positive Aβ aggregates by 9 weeks of culture | Synthetic Aβ | No ThS-positive Aβ aggregates by 9 weeks of culture | |
| [ | Aβ plaques by at 6 weeks [ | No evidence of Aβ aggregates by 10 weeks | Single treatment with aged APPPS1 or APP23 brain homogenate and | Extensive Aβ aggregates after 1 week | |
| Aβ plaques by 6 months [ | |||||
| WT mice | N/A | ||||
| APP-null mice | N/A | ||||
| [ | WT mice | N/A | No evidence of Aβ aggregates | Treatment with Clodronate to remove microglia and 4 treatments with synthetic Aβ42 | ThS-positive Aβ aggregates after two weeks |
| [ | WT mice | N/A | No evidence of Aβ aggregates | Treatment with clodronate to remove microglia and addition of Aβ42 oligomer solution | Increased ThT fluorescence after 1 week (suggests Aβ aggregate formation) |
|
| |||||
| [ | 3xTg-AD mice: | Extracellular Aβ deposits by 6 months | No evidence of Aβ or tau aggregates after 28 days of culture | N/A | N/A |
|
| |||||
| [ | Tg Mice expressing human 4R tau with the ΔK280 FTD mutation [ | Hyperphosphor-ylation and aggregation of tau by 5–10 months [ | ThS-positive cell bodies by 20 days | N/A | N/A |
| [ | PS19 tau mice: | PHF1-positive neuronal staining by 6 months in hippocampus, amygdala and spinal cord [ | No evidence of tau aggregation after 13 days of culturing | Recombinant tau fibrils added on days 3 and 6 of culturing | Tau aggregation in hippocampal CA1 neurons 10 days after first seeding |
| WT mice | N/A | No evidence of tau aggregation 10 days after first seeding | |||
|
| |||||
| [ | WT rats | N/A | N/A | Treated on day 13/14 with monomeric α-syn, fibrillar α-syn, or a mixture of both exogenous forms | α-syn monomers did not cause cell death |
| [ | WT mice | N/A | N/A | α-syn fibrils microinjected into the dentate gyrus | α-syn aggregates appeared in the dentate gyrus after 3 days and in CA1 and CA3 by 3–5 days (no evidence of aggregates when monomeric α-syn injected) |
| SNCA knockout mice | No evidence of α-syn aggregates | ||||
| [ | WT mice | N/A | N/A | Primary ROSAmT/mG astrocytes were incubated with Alexa-488-labeled α-syn fibrils for 16 h. The astrocytes were then added on top of slice culture | α-syn inclusions observed in slice culture astrocytes but not neurons after 3–6 days |
| [ | WT mice | N/A | N/A | α-syn fibrils of 5 different polymorphs were added to slice cultures | α-syn aggregates were observed after 4–7 days. Extent and rate of aggregation depended on fibril polymorph |
|
| |||||
| [ | Tg mice expressing human G85R mutant SOD1-YFP fusion protein | Develop fluorescent SOD1 puncta in anterior horn of spinal cord by 9 months in cell bodies and neuropil [ | (spinal cord culture) | Treatment with spinal cord homogenates from paralyzed G85R SOD1:YFP mice that had been occulated with different “mouse-adapted” ALS strains1 | SOD1 aggregates induced in spinal cord slices |
| Treatment with spinal cord homogenates from sporadic or familial ALS patients | SOD1-YFP punctate inclusions by 7 days only when treated with A4V SOD1 mutation | ||||
| [ | Tg mice expressing human G85R mutant SOD1-YFP fusion protein | Develop fluorescent SOD1 puncta in anterior horn of spinal cord by 9 months in both cell bodies and neuropil [ | (spinal cord culture) | WT SOD1 was modified with various acyl groups and aggregated in vitro. The resulting ThT-positive or negative fibrils were then added to slice culture. | After 1 month of culture, only treatment with ThT-positive fibrils led to the formation of SOD1-YFP inclusions |
|
| |||||
| [ | R6/2 mice: | Develop mHtt aggregates in CA1 of hippocampus by 3 weeks and in CA3 by 5 weeks [ | mHtt aggregates are observed in CA1 of the hippocampus by 2 weeks and in CA3 and dentate gyrus by 3 weeks [ | N/A | N/A |
| [ | WT mice | N/A | Cortex or Striatum culture | WT-R6/2 Cocultures: | mHtt aggregates spread from R6/2 cortex to MSNs in WT striatum by 4 weeks, but not from R6/2 striatum to WT cortex |
All cultures are hippocampal unless otherwise indicated. 1 In the experiment by Ayers et al., (2016), G85R-SOD1-YFP mice were inoculated with homogenates from various mutant SOD1 mouse lines, including G93A, G37R, and L126Z, or with WT SOD1 fibrils. Spinal cord homogenates were then taken from these initially inoculated mice and passaged a second time into G85R-SOD1-YFP mice. Homogenates from these mice were then used to seed SOD1 aggregation in spinal cord slice cultures from G85R-SOD1-YFP mice.